HK1222134A1 - 治疗人的实体肿瘤的诺氏梭菌 - Google Patents
治疗人的实体肿瘤的诺氏梭菌 Download PDFInfo
- Publication number
- HK1222134A1 HK1222134A1 HK16110438.1A HK16110438A HK1222134A1 HK 1222134 A1 HK1222134 A1 HK 1222134A1 HK 16110438 A HK16110438 A HK 16110438A HK 1222134 A1 HK1222134 A1 HK 1222134A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- human
- novyi
- methods
- solid tumor
- sup
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Reproductive Health (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361806497P | 2013-03-29 | 2013-03-29 | |
| US61/806,497 | 2013-03-29 | ||
| PCT/US2014/032196 WO2014160950A1 (en) | 2013-03-29 | 2014-03-28 | C. novyi for the treatment of solid tumors in humans |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1222134A1 true HK1222134A1 (zh) | 2017-06-23 |
Family
ID=51625539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16110438.1A HK1222134A1 (zh) | 2013-03-29 | 2014-03-28 | 治疗人的实体肿瘤的诺氏梭菌 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10617723B2 (enExample) |
| EP (4) | EP4108248B1 (enExample) |
| JP (6) | JP6756609B2 (enExample) |
| KR (1) | KR20160021084A (enExample) |
| CN (2) | CN116570628A (enExample) |
| AU (2) | AU2014240872A1 (enExample) |
| BR (2) | BR112015024621B1 (enExample) |
| CA (2) | CA3206655A1 (enExample) |
| DK (1) | DK2988760T3 (enExample) |
| ES (3) | ES2815564T3 (enExample) |
| HK (1) | HK1222134A1 (enExample) |
| IL (1) | IL241823B (enExample) |
| MX (1) | MX377118B (enExample) |
| NZ (1) | NZ712691A (enExample) |
| PH (1) | PH12015502260B1 (enExample) |
| RU (1) | RU2718670C2 (enExample) |
| SG (2) | SG11201508071VA (enExample) |
| UA (1) | UA120036C2 (enExample) |
| WO (1) | WO2014160950A1 (enExample) |
| ZA (2) | ZA201507412B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX378397B (es) * | 2014-03-31 | 2025-03-10 | Univ Johns Hopkins | Uso de bacterias, productos bacterianos, y otras entidades inmunorreguladoras en combinacion con anticuerpos anti antigeno 4 de linfocitos t citotoxicos (ctla-4) y/o anti proteina 1 de muerte celular programada (pd-1) para tratar neoplasias de tumor solido. |
| CN105912930B (zh) * | 2016-04-11 | 2019-02-01 | 北京奇虎科技有限公司 | 移动终端及其系统资源安全控制方法 |
| US10815534B2 (en) | 2016-08-23 | 2020-10-27 | Mayo Foundation For Medical Education And Research | Methods and materials for treating estrogen receptor positive breast cancer |
| US20210085663A1 (en) * | 2017-05-16 | 2021-03-25 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating cancer with atypical braf mutations |
| CN109985039A (zh) * | 2017-12-29 | 2019-07-09 | 深圳微芯生物科技股份有限公司 | 用于治疗白血病的联合用药物及其在制备用于治疗急性髓性白血病的药物中的用途 |
| WO2021231611A1 (en) * | 2020-05-12 | 2021-11-18 | Splash Pharmaceuticals, Inc. | Methods for treating cancer using spl-108 polypeptide based on tp53 mutational status |
| US11717787B2 (en) * | 2021-01-04 | 2023-08-08 | Saudi Arabian Oil Company | High free volume membrane for gas separation |
| JP2024511277A (ja) | 2021-02-19 | 2024-03-13 | メビオン・メディカル・システムズ・インコーポレーテッド | 粒子線治療システムのためのガントリー |
| CN113855710B (zh) * | 2021-10-09 | 2024-02-20 | 施慧达药业集团(吉林)有限公司 | 戈氏梭菌联合肿瘤血管生成抑制剂的应用 |
| CN115350145A (zh) * | 2022-09-06 | 2022-11-18 | 华中科技大学同济医学院附属协和医院 | 细菌介导负载二甲双胍的多肽水凝胶在肿瘤免疫治疗中的应用 |
| JP7725011B1 (ja) * | 2024-02-01 | 2025-08-19 | ミヤリサン製薬株式会社 | Ｃｄ４－ｃｄ８－ｔ細胞を増殖および／または活性化させるための組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599331A (en) | 1984-12-24 | 1986-07-08 | Syntex (U.S.A.) Inc. | Etianic acids as antiangiogenics |
| WO1987002672A1 (en) | 1985-10-23 | 1987-05-07 | The Upjohn Company | Tetrahydro angiostatic steroids |
| US4771042A (en) | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| AU5640390A (en) | 1989-06-16 | 1991-01-08 | Upjohn Company, The | Suramin type compounds and angiostatic steroids to inhibit angiogenesis |
| DE69232925T2 (de) | 1991-11-22 | 2003-06-18 | Alcon Laboratories, Inc. | Angiostatische steroide |
| AU2002250170B2 (en) | 2001-02-28 | 2006-08-10 | Rex Medical, L.P. | Apparatus for Delivering Ablation Fluid to Treat Lesions |
| AU2002350235A1 (en) * | 2001-11-21 | 2003-06-10 | The Johns Hopkins University | Combination bacteriolytic therapy for the treatment of tumors |
| WO2005018332A1 (en) * | 2003-08-13 | 2005-03-03 | The General Hospital Corporation | Modified microorganisms for anti-cancer therapy |
| ATE459364T1 (de) | 2003-10-22 | 2010-03-15 | Univ Johns Hopkins | Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren |
| US20070015738A1 (en) * | 2005-07-15 | 2007-01-18 | Walker Stephen G | Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells |
| TW200819540A (en) * | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
| US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
-
2014
- 2014-03-28 ES ES14774988T patent/ES2815564T3/es active Active
- 2014-03-28 NZ NZ712691A patent/NZ712691A/en unknown
- 2014-03-28 AU AU2014240872A patent/AU2014240872A1/en not_active Abandoned
- 2014-03-28 MX MX2015013784A patent/MX377118B/es active IP Right Grant
- 2014-03-28 EP EP22171112.0A patent/EP4108248B1/en active Active
- 2014-03-28 ES ES20167187T patent/ES2922378T3/es active Active
- 2014-03-28 SG SG11201508071VA patent/SG11201508071VA/en unknown
- 2014-03-28 BR BR112015024621-4A patent/BR112015024621B1/pt active IP Right Grant
- 2014-03-28 KR KR1020157031284A patent/KR20160021084A/ko not_active Ceased
- 2014-03-28 EP EP14774988.1A patent/EP2988760B1/en active Active
- 2014-03-28 SG SG10201902765VA patent/SG10201902765VA/en unknown
- 2014-03-28 WO PCT/US2014/032196 patent/WO2014160950A1/en not_active Ceased
- 2014-03-28 CN CN202310166182.9A patent/CN116570628A/zh active Pending
- 2014-03-28 RU RU2015146199A patent/RU2718670C2/ru active
- 2014-03-28 EP EP20167187.2A patent/EP3730146B1/en active Active
- 2014-03-28 BR BR122020006408-0A patent/BR122020006408B1/pt active IP Right Grant
- 2014-03-28 CN CN201480028119.8A patent/CN105451750B/zh active Active
- 2014-03-28 US US14/781,273 patent/US10617723B2/en active Active
- 2014-03-28 CA CA3206655A patent/CA3206655A1/en active Pending
- 2014-03-28 JP JP2016505594A patent/JP6756609B2/ja active Active
- 2014-03-28 CA CA2908508A patent/CA2908508C/en active Active
- 2014-03-28 DK DK14774988.1T patent/DK2988760T3/da active
- 2014-03-28 PH PH1/2015/502260A patent/PH12015502260B1/en unknown
- 2014-03-28 EP EP25202057.3A patent/EP4653054A2/en active Pending
- 2014-03-28 ES ES22171112T patent/ES3048113T3/es active Active
- 2014-03-28 HK HK16110438.1A patent/HK1222134A1/zh unknown
- 2014-03-28 UA UAA201510523A patent/UA120036C2/uk unknown
-
2015
- 2015-09-24 IL IL241823A patent/IL241823B/en active IP Right Grant
- 2015-10-06 ZA ZA2015/07412A patent/ZA201507412B/en unknown
-
2017
- 2017-02-14 JP JP2017025263A patent/JP2017088619A/ja active Pending
- 2017-09-21 ZA ZA2017/06402A patent/ZA201706402B/en unknown
-
2018
- 2018-10-26 JP JP2018201792A patent/JP2019011376A/ja active Pending
-
2019
- 2019-01-17 AU AU2019200276A patent/AU2019200276B2/en active Active
-
2020
- 2020-03-31 US US16/836,003 patent/US11439669B2/en active Active
- 2020-06-25 JP JP2020109387A patent/JP7445893B2/ja active Active
-
2021
- 2021-12-09 JP JP2021199949A patent/JP2022022392A/ja active Pending
-
2022
- 2022-08-02 US US17/816,924 patent/US20220378852A1/en active Pending
-
2024
- 2024-03-06 JP JP2024034039A patent/JP7788114B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1222134A1 (zh) | 治疗人的实体肿瘤的诺氏梭菌 | |
| WO2016025635A3 (en) | Combination therapy for treating cancer | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| MX375442B (es) | Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer. | |
| WO2019067666A8 (en) | Therapeutic methods relating to hsp90 inhibitors | |
| MX2018005071A (es) | Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp. | |
| NZ700759A (en) | Combination therapy for treating cancer | |
| MX2021004828A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| EP4424326A3 (en) | Modified nk-92 cells for treating cancer | |
| WO2016043874A3 (en) | Combination therapy for treating cancer | |
| SG10201909199PA (en) | Method for treating cancer | |
| MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
| WO2016201450A3 (en) | Cancer treatment and diagnosis | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| WO2014153082A3 (en) | Systems and methods for treating prostate cancer | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| WO2015200828A8 (en) | Conjugates for immunotherapy | |
| MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
| MX2012010212A (es) | Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| MX2019013862A (es) | Terapia de combinacion. | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| WO2014160967A8 (en) | C. novyi for the treatment of solid tumors in non-human animals | |
| MX2016016388A (es) | Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña. |